Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 2/2016

01-02-2016 | Consensus Statement

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly

Authors: M. G. Baroni, F. Giorgino, V. Pezzino, C. Scaroni, A. Avogaro

Published in: Journal of Endocrinological Investigation | Issue 2/2016

Login to get access

Abstract

Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic decisions for the treatment of hyperglycemia in patients with growth hormone and corticosteroid excess. Both the SID and SIE appointed members to represent each society and to collaborate in Guidelines writing. Members were chosen for their specific knowledge in the field. Each member agreed to produce—and regularly update—conflicts of interest. The authors of these guidelines prepared their contributions following the recommendations for the development of Guidelines, using the standard classes of recommendation shown below. All members of the writing committee provided editing and systematic review of each part of the manuscript, and discussed the grading of evidence. Consensus was guided by a systematic review of all available trials and by interactive discussions.
Literature
1.
Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549–555CrossRef
2.
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a meta analysis. J Clin Endocrinol Metab 93:61–67PubMedCrossRef
3.
Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R, Tamburrano G (2001) Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 54:189–195CrossRef
4.
Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674PubMedCrossRef
5.
Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMed
6.
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRef
7.
Biering H, Knappe G, Gerl H, Lochs H (2000) Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 27:27–31PubMedCrossRef
8.
Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J of Med Biol Res 34:1429–1433CrossRef
9.
Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, French Acromegaly Registry (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877–884PubMedCrossRef
10.
11.
Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642PubMedCrossRef
12.
Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479–484CrossRef
13.
Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981PubMedCrossRef
14.
15.
Mazziotti G, Gazzaruso C, Giustina A (2011) Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 22:499–506PubMedCrossRef
16.
Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP (1996) Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 43:645–655PubMedCrossRef
17.
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 61:768–777CrossRef
18.
Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A, Yamauchi A (2007) Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105:c54–c57PubMedCrossRef
19.
Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M (2004) Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 24:508–514PubMedCrossRef
20.
Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, Cozzolino A, Colao A (2014) Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur J Endocrinol 170:311–319PubMedCrossRef
21.
Rizza RA, Mandarino LJ, Gerich JE, Effects of growth hormone on insulin action in man (1982) Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMedCrossRef
22.
Moller N, Schmitz O, Jorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J (1992) Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74:1012–1019PubMed
23.
Moller N, Butler PC, Antsiferov MA, Alberti KG (1989) Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 32:105–110PubMedCrossRef
24.
Nielsen S, Moller N, Christiansen JS, Jorgensen JO (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50:2301–2308PubMedCrossRef
25.
Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose–fatty acid cycle. J Clin Endocrinol Metab 88:1455–1463PubMedCrossRef
26.
Dominici FP, Cifone D, Bartke A, Turyn D (1999) Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone transgenic mice. J Endocrinol 161:383–392PubMedCrossRef
27.
Giorgino F, Pedrini MT, Matera L, Smith RJ (1997) Specific increase in p85α expression in response to dexamethasone is associated with inhibition of Insulin-like Growth Factor-I stimulated phosphatidylinosito I 3-kinase activity in cultured muscle cells. J Biol Chem 272:7455–7463PubMedCrossRef
28.
Barbour LA, Rahman SM, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, McCurdy CE, Yakar S, LeRoith D, Kahn CR, Cantley LC, Friedman JE, Draznin B (2005) Increased p85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280:37489–37494PubMedCrossRef
29.
Del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, Kopchick JJ, Friedman JE, Draznin B, Thorner MO (2007) Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56:1638–1646PubMedCrossRef
30.
Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152–177PubMedCrossRef
31.
van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39:81–93PubMedCrossRef
32.
McMahon M, Gerich J, Rizza R (1988) Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 4:17–30PubMedCrossRef
33.
Kraus-Friedman N (1984) Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64:170–259
34.
Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L (2000) Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 19:29–34PubMedCrossRef
35.
Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ (1993) Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 91:2020–2030PubMedPubMedCentralCrossRef
36.
Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A (2010) Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):77–81PubMedCrossRef
37.
38.
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556PubMedCrossRef
39.
Gremlich S, Roduit R, Thorens B (1997) Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 272:3216–3222PubMedCrossRef
40.
Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall’Omo AM, Imbimbo B (1983) An in vivo and in vitro study of the mechanism of prednisone- induced insulin resistance in healthy subjects. J Clin Invest 72:1814–1820PubMedPubMedCentralCrossRef
41.
Wajngot A, Giacca A, Grill V, Vranic M, Efendic S (1992) The diabetogenic effects of glucocorticoids are more pro- nounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 89:6035–6039PubMedPubMedCentralCrossRef
42.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517PubMedCrossRef
43.
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, HO K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef
44.
Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly: 2011 Update. Endocr Pract 17(Suppl 4):1–44PubMedCrossRef
45.
Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, First-line Ghigo E (2006) Therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly Primary Medical Treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29:1017–1020PubMedCrossRef
46.
Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314PubMedCrossRef
47.
Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518–523PubMedCrossRef
48.
Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(4405):4410
49.
Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results. J Clin Endocrinol Metab 88:3090–3098PubMedCrossRef
50.
Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 64:342–351CrossRef
51.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177PubMedCrossRef
52.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754–1759PubMedCrossRef
53.
Wasada T, Aoki K, Sato A, Katsumori K, Muto K, Tomonaga O, Yokoyama H, Iwasaki N, Babazono T, Takahashi C, Iwamoto Y, Omori Y, Hizuka N (1997) Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J 44:617–620PubMedCrossRef
54.
Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved. Eur J Endocrinol 164:467–473PubMedCrossRef
55.
Battezzati A, Benedini S, Fattorini A, Losa M, Mortini P, Bertoli S, Lanzi R, Testolin G, Biolo G, Luzi L (2003) Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 284:E823–E829PubMedCrossRef
56.
Mori K, Iwasaki Y, Kawasaki-Ogita Y, Honjo S, Hamamoto Y, Tatsuoka H, Fujimoto K, Ikeda H, Wada Y, Takahashi Y, Takahashi J, Koshiyama H (2013) Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest 36:853–859PubMed
57.
Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94:528–537PubMedCrossRef
58.
Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, Vassilopoulos C (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf) 75:96–102CrossRef
59.
Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, Galluzzo A, Colao A (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15:539–551PubMedCrossRef
60.
Stelmachowska-Banaś M, Zieliński G, Zdunowski P, Podgórski J, Zgliczyński W (2011) The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol Neurochir Pol 45:328–334PubMed
61.
Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779–3785PubMedCrossRef
62.
Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, Lisák R, Vymazal J, Pecen L (2006) Gamma knife radiosurgery for acromegaly–long-term experience. Clin Endocrinol (Oxf) 64:588–595CrossRef
63.
Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, Sheehan J (2014) Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99:1273–1281PubMedCrossRef
64.
Fedele D, Molinari M, Meneghel A, Valerio A, Muggeo M, Tiengo A (1980) Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients. J Endocrinol Invest 3:149–153PubMedCrossRef
65.
Feek CM, Bevan JS, Taylor S, Brown NS, Baird JD (1981) The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly. Clin Endocrinol (Oxf) 15:473–478CrossRef
66.
Dolecek R, Kubis M, Sajnar J, Závada M (1982) Bromocriptine and glucose tolerance in acromegalics. Pharmatherapeutica 3:100–106PubMed
67.
Chiba T, Chihara K, Minamitani N, Goto B, Kadowaki S, Taminato T, Matsukura S, Fujita T (1982) Effect of long term bromocriptine treatment on glucose intolerance in acromegaly. Horm Metab Res 14:57–61PubMedCrossRef
68.
Rau H, Althoff PH, Schmidt K, Badenhoop K, Usadel KH (1993) Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Investig 71:372–378PubMedCrossRef
69.
Roemmler J, Steffin B, Gutt B, Schneider HJ, Sievers C, Bidlingmaier M, Schopohl J (2010) The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res 20:338–344PubMedCrossRef
70.
Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187–1193PubMedCrossRef
71.
Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797–1804PubMedCrossRef
72.
Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103:458–465PubMedCrossRef
73.
McKnight JA, McCance DR, Crothers JG, Atkinson AB (1989) Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. Br Med J 299:604–605CrossRef
74.
James RA, Møller N, Chatterjee S, White M, Kendall-Taylor P (1991) Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med 8:517–523PubMedCrossRef
75.
Koop BL, Harris AG, Ezzat S (1994) Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581–586PubMedCrossRef
76.
Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M (1995) Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 27:226–230PubMedCrossRef
77.
Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G (1995) Effects of treatment with octreotide in acromegalic patients–a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133:430–439PubMedCrossRef
78.
Hizuka N (1997) Divergent effects of octreotide on glucose tolerance in patients with acromegaly. Intern Med 36:319–320PubMedCrossRef
79.
Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73–78PubMedCrossRef
80.
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500–1508PubMedCrossRef
81.
Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M (2002) Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502–507PubMedCrossRef
82.
Ronchi C, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-yeartherapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128PubMedCrossRef
83.
Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492–499CrossRef
84.
Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective stuidy of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397–1403PubMedCrossRef
85.
Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94:2907–2914PubMedCrossRef
86.
Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164:341–347PubMedCrossRef
87.
Couture E, Bongard V, Maiza JC, Bennet A, Caron P (2012) Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 15:518–525PubMedCrossRef
88.
Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2012) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest 35:154–159PubMed
89.
Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LI (2013) Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc) 49:89–103CrossRef
90.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791–799PubMedPubMedCentral
91.
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide C2402 Study Group (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875–884PubMedCrossRef
92.
Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study Group (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781–2789PubMedCrossRef
93.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A (2014) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18:385–394PubMedCentralCrossRef
94.
Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87:1692–1699PubMedCrossRef
95.
Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ (2003) The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 59:168–174CrossRef
96.
Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormon IGF Res 12:418–424CrossRef
97.
Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521–527PubMedCrossRef
98.
Jorgensen JO, Feldt-Rasmussen U, Fgrystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627–5631PubMedCrossRef
99.
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75–82PubMedCrossRef
100.
De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A (2007) Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227–232PubMedCrossRef
101.
Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467–477PubMedCrossRef
102.
Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684–5691PubMedCrossRef
103.
Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jorgensen JO (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724–1728PubMedCrossRef
104.
Higham CE, Rowles S, Russel-Jones D, Umpleby AM, Trainer PJ (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459–2463PubMedCrossRef
105.
Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71:549–557CrossRef
106.
Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F (2013) Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 169:99–108PubMedCrossRef
107.
Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO (2011) Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 96:2405–2413PubMedCrossRef
108.
Kumar V, Gulatia RK, Ahuja MM (1971) A clinical and biochemical study of 12 cases of acromegaly with special reference to plasma I.R.I. and FFA on glibenclamide administration. J Assoc Phys India 19:623–677
109.
Watanabe A, Komine F, Nirei K, Tamura K, Nabe K, Aiba N, Kamoshida S, Otsuka M, Okubo H, Kanou M, Sawada S, Uchiyama T, Nakamura S, Arakawa Y (2004) A case of secondary diabetes mellitus with acromegaly improved by pioglitazone. Diabet Med 21:1049–1050PubMedCrossRef
110.
Kim DDW, Goh J, Panossian Z, Gamble G, Holdaway I, Grey A (2012) Pioglitazone in acromegaly: an open-label, prospective study. Clin Endocrinol (Oxf) 77:575–578CrossRef
111.
Arnaldi et al (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef
112.
113.
Mancini T et al (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag 21:505–516
114.
Gola M et al (2005) Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 90:1864–1870PubMedCrossRef
115.
Filipsson H et al (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961PubMedCrossRef
116.
Mazziotti G et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20PubMedCrossRef
117.
Zeiger MA et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incident alomas: executive summary of recommendations. Endocr. Pract. 15:450–453PubMedCrossRef
118.
Terzolo M et al (2007) Subclinical Cushing’s syndrome. Arq Bras Endocrinol Metabol 51:1272–1279PubMedCrossRef
119.
Colao A et al (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84:2664–2672PubMed
120.
Webb SM et al (2010) Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 95:630–638PubMedCrossRef
121.
Faggiano A et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533PubMedCrossRef
122.
Giordano R, Picu A, Marinazzo E et al (2011) Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75:354–360CrossRef
123.
Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47:9–20PubMedCrossRef
124.
125.
126.
127.
Castinetti F et al (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 158:91–99PubMedCrossRef
128.
Valassi E et al (2012) A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol 77:735–742CrossRef
129.
Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623–1630PubMedCrossRef
130.
Verhelst et al (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 35(2):169–178CrossRef
131.
Yoshida et al (2012) Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocrine 41:160–161PubMedCrossRef
132.
Omori et al (2001) Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). Endocr J 48(6):665–669PubMedCrossRef
133.
134.
Castinetti et al (2009) Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 160:1003–1010PubMedCrossRef
135.
Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL (1985) Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536–540PubMedCrossRef
136.
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568–3573PubMed
137.
Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C (2008) Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur J Endocrinol 158:935–938PubMedCrossRef
138.
Fleseriu et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with cushing’s syndrome. J Clin Endocrinol Metab 97(6):2039–2049PubMedCrossRef
139.
Pivonello et al (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230PubMedCrossRef
140.
Vilar L, Naves LA, Azevedo MF et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129PubMedCrossRef
141.
Barbot M, Albiger N, Ceccato F et al (2014) Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17(2):109–117PubMedCrossRef
142.
Pecori-Giraldi F et al (2006) Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s disease. Clin Endocrinol 64:219–224CrossRef
143.
Ambrosi B et al (2004) Effects of chronic administration of PPARgamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 151:173–178PubMedCrossRef
144.
Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J Clin Endocrinol Metab 90:1340–1346PubMedCrossRef
145.
Pecori Giraldi F, Ambrogio AG, Andrioli M et al (2012) Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 97(10):3577–3583PubMedCrossRef
146.
Schonbrunn A (1982) Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147–1154PubMedCrossRef
147.
Giustina A et al (1991) Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 14:47–54PubMedCrossRef
148.
Colao A, Petersenn S, Newell-Price J et al (2012) Asireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924PubMedCrossRef
149.
Boscaro M, Ludlam WH, Atkinson B et al (2009) Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115–122PubMedCrossRef
150.
Ben-Shlomo A et al (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94:4342–4350PubMedCrossRef
151.
Pedroncelli AM (2010) Medical treatment of Cushing’s disease: somatostatin analogues and pasireotide. Neuroendocrinology 92:120–124PubMedCrossRef
152.
Occhi G, Regazzo D, Albiger NM et al (2014) Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing’s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation. Endocrinology 155:3538–3549
153.
Mitra SW et al (1999) Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790–3796PubMed
154.
Petersenn S et al (2011) Pasireotide (SOM230), a novel multi-receptor targeted somatostatin analogue, is well tolerated when administered as a continuous 7 day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol 52:1017–1027PubMedCrossRef
155.
156.
157.
Henry et al (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453PubMedCrossRef
158.
Mackenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2013) Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17:519–529CrossRef
159.
Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2014) Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18:359–365CrossRef
160.
Feelders RA et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 362:1846–1848PubMedCrossRef
161.
162.
Taghavi SM, Fatemi SS, Rokni H (2012) Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med J Malaysia 67(4):390–392PubMed
163.
Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14(4):335–340PubMedPubMedCentralCrossRef
164.
Gurwitz JH et al (1994) Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154:97–101PubMedCrossRef
165.
Henriksen JE, Alford F, Ward GM, Beck-Nielsen H (1997) Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40:1439–1448PubMedCrossRef
166.
Darmon P et al (2006) Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol 291:E995–E1002CrossRef
167.
Donihi AC et al (2006) Prevalence and predictors of corticosteroid related hyperglycemia in hospitalized patients. Endocr Pract 12:358–362PubMedCrossRef
168.
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia. J. Diabetes 6(1):9–20CrossRef
169.
Mancini T et al (2009) Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45:784–788PubMedCrossRef
170.
Mazziotti G et al (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef
171.
Home PD et al (2007) Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 357:28–38PubMedCrossRef
172.
Van Raalte DH et al (2011) Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34:412–417PubMedPubMedCentralCrossRef
173.
Matsuo et al (2013) Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Intern Med 52:89–95PubMedCrossRef
174.
Dhital SM, Shenkery Y, Meredith M et al (2012) A retrospective study comparing neutral protamine hagedorm insulin with glargine as basal therapy in prednisone associated diabetes mellitus in hospitalized patients. Endocr Pract 18:712–719PubMedPubMedCentralCrossRef
175.
Lansang MC, Hustak LK (2011) Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med 78(11):748–756PubMedCrossRef
176.
Newell-Price (2010) Management of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):82–85PubMed
177.
Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA (2007) Preserved GLP-1 effects in a diabetic patient with Cushing’s disease. Exp Clin Endocrinol Diabetes 115:146–150PubMedCrossRef
178.
Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186PubMedPubMedCentralCrossRef
179.
Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Vergès B (2013) Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab 39(1):34–41PubMedCrossRef
180.
Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379PubMedPubMedCentralCrossRef
Metadata
Title
Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly
Authors
M. G. Baroni
F. Giorgino
V. Pezzino
C. Scaroni
A. Avogaro
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 2/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0404-6

Other articles of this Issue 2/2016

Journal of Endocrinological Investigation 2/2016 Go to the issue

Original Article

Thyroid Hürthle cell tumors: research of potential markers of malignancy

Original Article

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

Review

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

Original Article

Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine

Review

Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Original Article

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits